While many use marijuana for managing chronic pain or as a way to unwind at the end of the day, according to UW Medicine, ...

The U.S. FDA has approved narsoplimab (Yartemlea) as the first indicated therapy for hematopoietic stem cell ...

Health-related social needs in HF, removing age from frailty scores, CIED concerns about smartwatches, and more.

Omeros’ Yartemlea gets US FDA approval to treat hematopoietic stem cell transplant-associated thrombotic microangiopathy: Seattle Monday, December 29, 2025, 12:00 Hrs [IST] Omer ...

Omeros to Host Conference Call Monday, December 29, 2025 at 4:30 p.m. ET -- -- First and only approved option: YARTEMLEA(R) is the only approved treatment for hematopoietic stem cell ...

Omeros Corporation today announced that the U.S. Food and Drug Administration (FDA) has approved YARTEMLEA® (narsoplimab-wuug) for the treatment of hematopoietic stem cell transplant-associated ...

Omeros (OMER) receives FDA approval for Yartemlea (narsoplimab) in TA-TMA, driving shares up nearly 80% to a $1bn+ valuation.

This is the latest study to suggest that GLP-1s, particularly semaglutide, are tied to a reduced risk for epilepsy in type 2 diabetes.

Seborrheic dermatitis is associated with other epithelial barrier diseases of the skin and beyond, including the respiratory, ...

Background Multiple long-term conditions (MLTCs) are common among individuals with heart failure (HF); however, the influence ...

As COVID completes its sixth year, official statistics obscure the scale of harm, while Long COVID and excess deaths reveal ...

A recent study finds that six specific depressive symptoms in midlife may increase the risk of dementia later in life by ...